EO 104 was signed by President Rodrigo Roa Duterte on 17 February 2020. It aims to provide Filipinos with affordable healthcare through the imposition of a Maximum Retail Price (MRP) and/or Maximum Wholesale Price (MWP) on certain drugs and medicines based on a set criteria. EO 104 now imposes MRP and/or MWP on 86 drug molecules or 133 drug formulas covering treatment of illnesses like diabetes, hypertension, major types of cancer, cardiovascular disease, chronic lung diseases, depression, pain relief, psoriasis, among others. It further establishes a technical working group, composed of representatives from the Department of Health (DOH) and the Department of Trade and Industry (DTI), to review, in consultation with stakeholders, the prices of the remaining drug molecules previously proposed to be subject of the MRP or MWP. Retailers are given a non-extendible period of ninety (90) days from effectivity of the EO to dispose of their existing inventory at prevailing prices. Thereafter, the MRP and/or MWP shall be strictly implemented.
The list of drugs subject of MRP and MWP shall be subject to review by the DOH in consultation with DTI within 6 months from the effectivity of EO 104 and every 6 months thereafter.
For more information, please click link for a copy of the EO.